<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Thyroid gland dysfunction in the patient with HIV
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Thyroid gland dysfunction in the patient with HIV
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Thyroid gland dysfunction in the patient with HIV
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Melissa Weinberg, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Morris Schambelan, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rajesh T Gandhi, MD, FIDSA
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Milana Bogorodskaya, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 09, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Early in the acquired immunodeficiency syndrome (AIDS) epidemic, endocrine manifestations of human immunodeficiency virus (HIV) infection were often a consequence of opportunistic infections, neoplasms, or concomitant medical conditions. The widespread use of potent antiretroviral therapy in resource-rich settings has led to a decline in the incidence of glandular infiltration by opportunistic infections and neoplasms.
        </p>
        <p>
         This topic addresses the evaluation of thyroid disorders in patients with HIV. Issues related to pituitary and adrenal disorders, insulin resistance, bone and calcium disorders, and hypogonadism are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3720.html" rel="external">
          "Pituitary and adrenal gland dysfunction in patients with HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3733.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3700.html" rel="external">
          "Treatment of HIV-associated lipodystrophy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3738.html" rel="external">
          "Bone and calcium disorders in patients with HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13969.html" rel="external">
          "Hypogonadism in males with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          OVERVIEW
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, the approach to thyroid disorders in a patient with HIV is similar to that in an uninfected individual. However, HIV infection may also cause changes in thyroid function that are adaptive and do not require treatment. In addition, many of the symptoms and signs of thyroid dysfunction are nonspecific and can overlap with those of non-endocrine disorders that are common in patients with HIV. Lastly, some medications used to treat HIV infection and its complications can induce thyroid dysfunction. (See
         <a class="local">
          'Effects of medications'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          GLANDULAR INFILTRATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infection by a diverse array of organisms, as well as HIV-associated malignancies (eg, Kaposi sarcoma, lymphoma), have been detected in the thyroid gland in patients with AIDS  (
         <a class="graphic graphic_table graphicRef72716" href="/z/d/graphic/72716.html" rel="external">
          table 1
         </a>
         ). Such occurrences were far more common prior to the widespread use of potent antiretroviral therapy (ART), although they may still be observed in patients not receiving ART or who have developed antiretroviral drug resistance.
        </p>
        <p>
         The infrequency of infectious and neoplastic thyroid disease in patients with HIV was illustrated in a retrospective study of 102 autopsy cases in the United States from 1980 to 2007 [
         <a href="#rid1">
          1
         </a>
         ]. Interstitial fibrosis and thyroid hyperplasia were the most common histologic findings (5 and 2 percent of cases, respectively), whereas infection was identified in fewer than 3 percent and Kaposi sarcoma was present in only one case.
        </p>
        <p>
         Glandular infiltration may be suspected on clinical grounds or as the result of an imaging study (eg, ultrasound). Tissue is generally required for a definitive diagnosis. Fine-needle aspiration of the thyroid is safe, effective, and widely available. Functional testing with a thyroid-stimulating hormone level should also be performed since thyroid dysfunction may accompany glandular infection or infiltration.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          ALTERATIONS IN THYROID FUNCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Disturbances in thyroid function can lead to hypo- or hyperthyroidism, which can be asymptomatic or clinically overt. The presentation and diagnosis of thyroid disorders is discussed in detail elsewhere (see
         <a class="medical medical_review" href="/z/d/html/7893.html" rel="external">
          "Diagnosis of and screening for hypothyroidism in nonpregnant adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7847.html" rel="external">
          "Diagnosis of hyperthyroidism"
         </a>
         ). The effect of HIV infection on thyroid function is discussed below. (See
         <a class="local">
          'Effects of medications'
         </a>
         below.)
        </p>
        <p>
         Asymptomatic patients with HIV with stable body weight generally maintain normal thyroid function [
         <a href="#rid2">
          2,3
         </a>
         ]. By contrast, changes similar to those seen in non-thyroidal illness (NTI) in uninfected individuals are often present in patients with AIDS [
         <a href="#rid4">
          4
         </a>
         ]. NTI is generally characterized by low to normal thyroid-stimulating hormone (TSH), low tri-iodothyronine (T3), high reverse T3 (rT3), and normal free thyroxine (T4) levels related to impaired peripheral T4 to T3 conversion and reduced rT3 clearance. Low T3 levels in NTI may be adaptive by lowering metabolic rate and decreasing protein catabolism in the setting of systemic illness or reduced caloric intake [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7817.html" rel="external">
          "Thyroid function in nonthyroidal illness"
         </a>
         .)
        </p>
        <p>
         However, T3 levels are often higher and rT3 levels lower in AIDS patients than expected for NTI, raising concern that these protective effects may be compromised [
         <a href="#rid6">
          6
         </a>
         ]. The difference in T3 levels is not explained by the increased levels of thyroid hormone-binding globulin (TBG) seen in individuals with HIV [
         <a href="#rid7">
          7
         </a>
         ]. Reduction in T3 levels are sometimes observed in AIDS patients with opportunistic infections and anorexia [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1207792289">
         <span class="h2">
          Prevalence of thyroid dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several cross-sectional studies of patients with HIV suggest that the prevalence of thyroid dysfunction is high [
         <a href="#rid8">
          8-13
         </a>
         ]. However, in the modern combination antiretroviral therapy (ART) era, there may be no increased risk of thyroid dysfunction among those who have achieved full viral suppression. In a cohort of 826 people living with HIV (95 percent with undetectable viral loads), there was no difference in the prevalence of either hypo- or hyperthyroidism compared with 2503 matched uninfected controls [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         Thyroid dysfunction appears to be more prevalent in those with more advanced HIV disease. One multicenter study of 350 patients with HIV reported a 16 percent prevalence of hypothyroidism, although there was no uninfected control group for comparison [
         <a href="#rid8">
          8
         </a>
         ]. The risk of hypothyroidism was increased among patients with lower CD4 counts. Symptoms ranged from overt hypothyroidism (2.6 percent) to subclinical disease (6.6 percent) to an isolated low free T4 level (6.8 percent).
        </p>
        <p>
         In another study of newly diagnosed patients with HIV with advanced immunodeficiency (71 percent had a CD4 count &lt;200 cells/microL), the overall prevalence of thyroid dysfunction was 76 percent compared with 16 percent among a control group of healthy volunteers [
         <a href="#rid10">
          10
         </a>
         ]. Subclinical hypothyroidism was again the most common abnormality, affecting almost 53 percent of patients. Thyroid dysfunction correlated with declining CD4 counts. In clinical practice, however, many of these patients probably do not require treatment. (See
         <a class="medical medical_review" href="/z/d/html/7883.html" rel="external">
          "Subclinical hypothyroidism in nonpregnant adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Effects of medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thyroid dysfunction is more frequent in patients on ART compared with ART-naïve patients, usually manifesting as hypothyroidism [
         <a href="#rid13">
          13,15
         </a>
         ]. One study of 410 patients with HIV reported that increased TSH was associated with ART duration and nucleoside reverse-transcriptase inhibitor (NRTI) use [
         <a href="#rid12">
          12
         </a>
         ]. Another cross-sectional study of 117 patients with HIV reported a fourfold risk of subclinical hypothyroidism among those who had a history of
         <a class="drug drug_general" data-topicid="9946" href="/z/d/drug information/9946.html" rel="external">
          stavudine
         </a>
         (older NRTI) use [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         By increasing clearance of thyroid hormone, some medications (eg,
         <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">
          ritonavir
         </a>
         ,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         ) may precipitate clinical hypothyroidism in patients with HIV and marginal thyroid reserve. These medications may increase the metabolism of
         <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">
          levothyroxine
         </a>
         through induction of glucuronidation. Cases of hypothyroidism have been reported when levothyroxine is coadministered with ritonavir,
         <a class="drug drug_general" data-topicid="8558" href="/z/d/drug information/8558.html" rel="external">
          indinavir
         </a>
         , or lopinavir/ritonavir [
         <a href="#rid16">
          16,17
         </a>
         ]. Patients on thyroid replacement therapy should have thyroid hormone values monitored closely with dose adjustment of levothyroxine if necessary.
        </p>
        <p class="headingAnchor" id="H1039878627">
         <span class="h2">
          Effects of immune reconstitution inflammatory syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         When potent ART leads to immune reconstitution, autoimmune thyroid diseases can result from the production of new immune cells targeting thyroid antigens [
         <a href="#rid18">
          18
         </a>
         ]. Such patients typically present with symptoms and signs of Graves' disease one to two years after beginning ART [
         <a href="#rid19">
          19-23
         </a>
         ]. These patients generally have low or undetectable viral loads and no preexisting thyroid disease. Occasionally, they may develop associated thyroid eye disease [
         <a href="#rid24">
          24
         </a>
         ]. Response to treatment is not different than other patients with Graves’ disease [
         <a href="#rid25">
          25
         </a>
         ]. Immune reconstitution inflammatory syndrome can also lead to development of Hashimoto's thyroiditis [
         <a href="#rid26">
          26
         </a>
         ], which may explain reports suggesting an increased prevalence of hypothyroidism among patients on ART [
         <a href="#rid8">
          8,9,15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3762.html" rel="external">
          "Immune reconstitution inflammatory syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          ASSESSMENT OF THYROID FUNCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The changes in thyroid function tests described above usually do not require treatment and should be interpreted in their appropriate clinical context. If a patient with HIV presents with typical symptoms and/or signs of hypo- or hyperthyroidism (see
         <a class="medical medical_review" href="/z/d/html/7846.html" rel="external">
          "Clinical manifestations of hypothyroidism"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7833.html" rel="external">
          "Overview of the clinical manifestations of hyperthyroidism in adults"
         </a>
         ), thyroid-stimulating hormone should be the initial laboratory test ordered. If there is reason to suspect secondary (pituitary) hypothyroidism, then a free T4 should also be checked. Even though some studies have reported increased prevalence of hypothyroidism in patients with HIV [
         <a href="#rid8">
          8
         </a>
         ], we do not suggest routine screening in this population.
        </p>
        <p class="headingAnchor" id="H3323442663">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H2742593018">
         <span class="h2">
          Hypothyroidism
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with AIDS or wasting who are diagnosed with symptomatic hypothyroidism, we initially prescribe a low dose of thyroid replacement hormone (eg,
         <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">
          levothyroxine
         </a>
         25 to 50 mcg daily) with gradual upward titration and monitoring of thyroid function tests. Other patients with HIV are treated similarly to the general population. (See
         <a class="medical medical_review" href="/z/d/html/7855.html" rel="external">
          "Treatment of primary hypothyroidism in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H64461020">
         <span class="h2">
          Hyperthyroidism
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of the patient with HIV with hyperthyroidism is similar to that of the general population, with the notable exception that a tender thyroid gland in a patient with AIDS warrants fine-needle aspiration to exclude opportunistic infection or neoplasm. (See
         <a class="medical medical_review" href="/z/d/html/7886.html" rel="external">
          "Disorders that cause hypothyroidism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4174590489">
         <span class="h2">
          Thyroid nodules
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thyroid nodules that meet certain size or radiologic criteria also require fine-needle aspiration to rule out malignancy. (See
         <a class="medical medical_review" href="/z/d/html/7890.html" rel="external">
          "Diagnostic approach to and treatment of thyroid nodules"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2753774570">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111628.html" rel="external">
          "Society guideline links: Primary care of adults with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Early in the AIDS epidemic, endocrine manifestations of HIV infection were often a consequence of opportunistic infections, neoplasms, or concomitant medical conditions. The widespread use of potent antiretroviral therapy (ART) in the developed world has led to a decline in the incidence of glandular infiltration by opportunistic infections and neoplasms. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In general, the approach to thyroid disorders in a patient with HIV is similar to that in an uninfected individual. However, HIV infection may also cause changes in thyroid function that are adaptive and do not require treatment. (See
         <a class="local">
          'Overview'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infection by a diverse array of organisms, as well as HIV-associated malignancies (eg, Kaposi sarcoma, lymphoma), have been detected in the thyroid gland in patients with AIDS  (
         <a class="graphic graphic_table graphicRef72716" href="/z/d/graphic/72716.html" rel="external">
          table 1
         </a>
         ). Tissue is generally required for a definitive diagnosis. (See
         <a class="local">
          'Glandular infiltration'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with AIDS may have laboratory evidence of non-thyroidal illness, and there is higher prevalence of subclinical hypothyroidism in this population. People living with HIV who are well-treated with combination ART may not have an increased risk for thyroid dysfunction. (See
         <a class="local">
          'Alterations in thyroid function'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Certain medications, such as
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         and
         <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">
          ritonavir
         </a>
         , can precipitate clinical hypothyroidism in patients with HIV with marginal thyroid reserve. (See
         <a class="local">
          'Effects of medications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immune reconstitution after initiation of potent ART can sometimes lead to Graves' disease or Hashimoto's thyroiditis. (See
         <a class="local">
          'Effects of immune reconstitution inflammatory syndrome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In most instances, the management of hypo- and hyperthyroidism in the patient with HIV is similar to that of the general population. However, in patients with AIDS or wasting diagnosed with symptomatic hypothyroidism, we initially prescribe a low dose of thyroid replacement hormone with gradual upward titration and monitoring of thyroid function tests. In patients with AIDS diagnosed with hyperthyroidism who have a tender thyroid gland, fine-needle aspiration is warranted to rule out opportunistic infection or neoplasm. Thyroid nodules that meet certain size or radiologic criteria also require fine-needle aspiration to rule out malignancy. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4138889031">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate gratefully acknowledges John G Bartlett, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Infectious Diseases.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Cherqaoui R, Shakir KM, Shokrani B, et al. Histopathological Changes of the Thyroid and Parathyroid Glands in HIV-Infected Patients. J Thyroid Res 2014; 2014:364146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hommes MJ, Romijn JA, Godfried MH, et al. Increased resting energy expenditure in human immunodeficiency virus-infected men. Metabolism 1990; 39:1186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lambert M. Thyroid dysfunction in HIV infection. Baillieres Clin Endocrinol Metab 1994; 8:825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sellmeyer DE, Grunfeld C. Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. Endocr Rev 1996; 17:518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wartofsky L, Burman KD. Alterations in thyroid function in patients with systemic illness: the "euthyroid sick syndrome". Endocr Rev 1982; 3:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LoPresti JS, Fried JC, Spencer CA, Nicoloff JT. Unique alterations of thyroid hormone indices in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989; 110:970.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grunfeld C, Pang M, Doerrler W, et al. Indices of thyroid function and weight loss in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Metabolism 1993; 42:1270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beltran S, Lescure FX, Desailloud R, et al. Increased prevalence of hypothyroidism among human immunodeficiency virus-infected patients: a need for screening. Clin Infect Dis 2003; 37:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson M, Powles T, Zeitlin A, et al. Thyroid dysfunction and relationship to antiretroviral therapy in HIV-positive individuals in the HAART era. J Acquir Immune Defic Syndr 2009; 50:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dev N, Sahoo R, Kulshreshtha B, et al. Prevalence of thyroid dysfunction and its correlation with CD4 count in newly-diagnosed HIV-positive adults--a cross-sectional study. Int J STD AIDS 2015; 26:965.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silva GA, Andrade MC, Sugui Dde A, et al. Association between antiretrovirals and thyroid diseases: a cross-sectional study. Arch Endocrinol Metab 2015; 59:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hatzl M, Öllinger A, Geit M, et al. Thyroid screening in HIV-infected patients with antiretroviral therapy. Wien Klin Wochenschr 2015; 127:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ji S, Jin C, Höxtermann S, et al. Prevalence and Influencing Factors of Thyroid Dysfunction in HIV-Infected Patients. Biomed Res Int 2016; 2016:3874257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harsløf M, Knudsen AD, Benfield T, et al. No evidence of increased risk of thyroid dysfunction in well treated people living with HIV. AIDS 2018; 32:2195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madeddu G, Spanu A, Chessa F, et al. Thyroid function in human immunodeficiency virus patients treated with highly active antiretroviral therapy (HAART): a longitudinal study. Clin Endocrinol (Oxf) 2006; 64:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Touzot M, Beller CL, Touzot F, et al. Dramatic interaction between levothyroxine and lopinavir/ritonavir in a HIV-infected patient. AIDS 2006; 20:1210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sahajpal R, Ahmed RA, Hughes CA, Foisy MM. Probable interaction between levothyroxine and ritonavir: Case report and literature review. Am J Health Syst Pharm 2017; 74:587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jubault V, Penfornis A, Schillo F, et al. Sequential occurrence of thyroid autoantibodies and Graves' disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients. J Clin Endocrinol Metab 2000; 85:4254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilquin J, Viard JP, Jubault V, et al. Delayed occurrence of Graves' disease after immune restoration with HAART. Highly active antiretroviral therapy. Lancet 1998; 352:1907.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crum NF, Ganesan A, Johns ST, Wallace MR. Graves disease: an increasingly recognized immune reconstitution syndrome. AIDS 2006; 20:466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rasul S, Delapenha R, Farhat F, et al. Graves' Disease as a Manifestation of Immune Reconstitution in HIV-Infected Individuals after Initiation of Highly Active Antiretroviral Therapy. AIDS Res Treat 2011; 2011:743597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ludgate S, Connolly SP, Fennell D, et al. Graves' disease associated with HIV disease and late immune reconstitution inflammatory syndrome following the initiation of antiretroviral therapy. Endocrinol Diabetes Metab Case Rep 2021; 2021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jariyawattanarat V, Sungkanuparph S, Sriphrapradang C. CHARACTERISTICS OF GRAVES DISEASE IN HIV-INFECTED PATIENTS ON ANTIRETROVIRAL THERAPY. Endocr Pract 2020; 26:612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nallu R, Madhavan P, Chirch L, Luthra P. Thyroid Eye Disease due to Immune Reconstitution Inflammatory Syndrome as a Consequence of Antiretroviral Therapy in the Setting of AIDS. Case Rep Endocrinol 2020; 2020:1728423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawal IO, Orunmuyi AT, Popoola GO, et al. Immune reconstitution inflammatory syndrome-associated Graves disease in HIV-infected patients: clinical characteristics and response to radioactive iodine therapy. HIV Med 2021; 22:907.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinit RB, Leung JH, Hwang WS, et al. An Unusual Case of Hashimoto's Thyroiditis Presenting as Impending Cardiac Tamponade in a Patient with Acquired Immune Deficiency Syndrome (AIDS). Am J Case Rep 2021; 22:e929249.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3744 Version 29.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24587936" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Histopathological Changes of the Thyroid and Parathyroid Glands in HIV-Infected Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2233280" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Increased resting energy expenditure in human immunodeficiency virus-infected men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7811224" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Thyroid dysfunction in HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8897023" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6806085" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Alterations in thyroid function in patients with systemic illness: the "euthyroid sick syndrome".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2567143" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Unique alterations of thyroid hormone indices in the acquired immunodeficiency syndrome (AIDS)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8412739" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Indices of thyroid function and weight loss in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12905143" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Increased prevalence of hypothyroidism among human immunodeficiency virus-infected patients: a need for screening.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19092451" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Thyroid dysfunction and relationship to antiretroviral therapy in HIV-positive individuals in the HAART era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25505045" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Prevalence of thyroid dysfunction and its correlation with CD4 count in newly-diagnosed HIV-positive adults--a cross-sectional study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25993673" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Association between antiretrovirals and thyroid diseases: a cross-sectional study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25739648" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Thyroid screening in HIV-infected patients with antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27200374" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Prevalence and Influencing Factors of Thyroid Dysfunction in HIV-Infected Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30005023" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : No evidence of increased risk of thyroid dysfunction in well treated people living with HIV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16584508" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Thyroid function in human immunodeficiency virus patients treated with highly active antiretroviral therapy (HAART): a longitudinal study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16691080" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Dramatic interaction between levothyroxine and lopinavir/ritonavir in a HIV-infected patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28389458" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Probable interaction between levothyroxine and ritonavir: Case report and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11095463" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Sequential occurrence of thyroid autoantibodies and Graves' disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9863795" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Delayed occurrence of Graves' disease after immune restoration with HAART. Highly active antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16439886" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Graves disease: an increasingly recognized immune reconstitution syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21804938" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Graves' Disease as a Manifestation of Immune Reconstitution in HIV-Infected Individuals after Initiation of Highly Active Antiretroviral Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34612207" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Graves' disease associated with HIV disease and late immune reconstitution inflammatory syndrome following the initiation of antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31968184" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : CHARACTERISTICS OF GRAVES DISEASE IN HIV-INFECTED PATIENTS ON ANTIRETROVIRAL THERAPY.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32099691" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Thyroid Eye Disease due to Immune Reconstitution Inflammatory Syndrome as a Consequence of Antiretroviral Therapy in the Setting of AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34328251" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Immune reconstitution inflammatory syndrome-associated Graves disease in HIV-infected patients: clinical characteristics and response to radioactive iodine therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34039947" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : An Unusual Case of Hashimoto's Thyroiditis Presenting as Impending Cardiac Tamponade in a Patient with Acquired Immune Deficiency Syndrome (AIDS).
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
